IL17A and diabetes mellitus: A study has shown that oral administration of anti-CD3 drugs delayed the onset of diabetes and reduced morbidity in non-obese diabetic (NOD) mice, the mechanism of which may be related to the regulation of interferon gamma (IFN-γ) and IL-17 (24).